E 5531

09/01/2004 - "E5531 is a potent inhibitor of the early hyperdynamic cardiovascular and later myocardial depression response seen in experimental human endotoxemia."
09/01/2004 - "To evaluate the efficacy of a novel lipopolysaccharide (LPS) antagonist, E5531, in blocking LPS-induced cardiac responses including myocardial depression (as assessed by relatively load-independent echocardiographic indices of contractility) in a human model of experimental endotoxemia. "
09/01/2004 - "Experimental human endotoxemia is associated with depression of load-independent contractility indices: prevention by the lipid a analogue E5531."
08/01/2000 - "E5531 blocks the symptoms and signs and cytokine, white blood cell count, C-reactive protein, and cardiovascular response seen in experimental endotoxemia. "
08/01/2000 - "A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia."

04/01/1999 - "E5531 suppressed the pyrogenicity of ETX in rabbits, indicating that E5531 is expected to be useful for the treatment of fever induced by ETX."
04/01/1999 - "The effect of the lipid A analog, E5531 on fever induced by endotoxin from Escherichia coli."

10/06/2003 - "E5531, a lipid A antagonist developed for therapeutic intervention of endotoxin shock, blocks LPS interaction with TLR4-MD-2 at a concentration 100 times lower than that required for blocking LPS interaction with CD14. "
06/01/1999 - "As part of a program aimed at developing a therapeutic agent for septic shock, we have developed E5531, a novel synthetic lipopolysaccharide antagonist. "
04/01/1999 - "E5531 is a specific lipid A antagonist and is expected to be a drug for the treatment of septic shock. "
06/01/1999 - "6. These results support our contention that E5531 is a potent antagonist of lipopolysaccharide-induced release of tumour necrosis factor-alpha and other cellular mediators and may be an effective therapeutic agent for human septic shock due to Gram-negative bacteria."
12/01/2004 - "In order to design an injectable formulation of E5531, a novel synthetic disaccharide analog of novel lipid A, for the treatment of septic shock, a 'pH-jump method' was developed. "

03/01/2000 - "E5531, a novel synthetic lipid A analogue, antagonizes the toxic effects of lipopolysaccharide, making it a potential intravenously administered therapeutic agent for the treatment of sepsis. "
08/01/1998 - "Endotoxin neutralizing protein (ENP)) and E5531 may have potential in the treatment of sepsis. "

06/01/1999 - "When 10 nM E5531 was added simultaneously with lipopolysaccharide or 1 - 3 h before addition of lipopolysaccharide, production of tumour necrosis factor-alpha was inhibited by more than 98%. "
06/01/1999 - "6. These results support our contention that E5531 is a potent antagonist of lipopolysaccharide-induced release of tumour necrosis factor-alpha and other cellular mediators and may be an effective therapeutic agent for human septic shock due to Gram-negative bacteria."
05/01/1999 - "E5531 is a synthetic disaccharide analogue of lipid A which has a low toxicity but retains the ability to reduce production of tumour necrosis factor. "